Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

被引：0
|
作者：
Qaisar, Aitzaz
Venugopal, Balaji
Ansel, Sonam
Jones, Robert J.
Slater, Sarah
Symeonides, Stefan N.
Malik, Jahangeer
Sundaramurthy, Aravindhan
Elliott, Tony
Devasar, Abeera
Stares, Mark
Randhawa, Manreet
机构：
[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[4] Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland
[5] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[6] NHS Lothian, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
716
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy
    Akihiro Yoshimura
    Yoshiyuki Yamamoto
    Tatsuya Nishikawa
    Masashi Fujita
    Takako Inoue
    Fuki Kondo
    Takuji Hayashi
    Norihiko Kawamura
    Akira Nagahara
    Yasutomo Nakai
    Masashi Nakayama
    Kazuo Nishimura
    International Cancer Conference Journal, 2024, 13 (1) : 26 - 32
  • [22] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [23] CARDIOTOXICITY IN METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS TREATED WITH SUNITINIB (SU)
    Ballatore, Valentina
    Prati, Veronica
    Ruatta, Fiorella
    Galizia, Danilo
    Grignani, Giovanni
    Aglietta, Massimo
    Ortega, Cinzia
    ANTICANCER RESEARCH, 2012, 32 (05) : 1876 - 1877
  • [24] Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).
    Arduini, Chiara
    Ciccarese, Chiara
    Acunzo, Alessandro
    Perrino, Matteo
    Maruzzo, Marco
    Verzoni, Elena
    Accettura, Caterina
    Bonomi, Lucia
    Buttigliero, Consuelo
    Cremante, Malvina
    Pipitone, Stefania
    Scartozzi, Mario
    Masini, Cristina
    Mollica, Veronica
    Primi, Francesca
    Strusi, Alessandro
    Buti, Sebastiano
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Iacovelli, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 551 - 551
  • [25] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Shimizu, Kazuki
    Tamada, Satoshi
    Matsuoka, Yudai
    Go, Ishun
    Okumura, Satoshi
    Ogawa, Masao
    Ohmachi, Tetsuji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022, 11 (03) : 205 - 209
  • [26] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Wan, Shuyan
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Kazuki Shimizu
    Satoshi Tamada
    Yudai Matsuoka
    Ishun Go
    Satoshi Okumura
    Masao Ogawa
    Tetsuji Ohmachi
    International Cancer Conference Journal, 2022, 11 : 205 - 209
  • [28] Biological toxicity as a predictive factor of efficacy in metastatic renal cell carcinoma (mRCC) treated with sunitinib
    Guillabert, P.
    Elaidi, R. T.
    Teghom, C.
    Medioni, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S651 - S651
  • [29] C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma
    Konishi, Sakae
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Tanaka, Toshikazu
    Hamano, Itsuto
    Fujita, Naoki
    Yoneyama, Tohru
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Masumori, Naoya
    Kitamura, Hiroshi
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (10) : 992 - 998
  • [30] Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib-refractory metastatic renal cell carcinoma (mRCC)
    Dutcher, Janice
    Garrett, May
    Wilding, George
    Stadler, Walter M.
    Pithavala, Yazdi
    Kim, Sinil
    Tarazi, Jamal
    Rixe, Olivier
    Rini, Brian I.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
12345